Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-blind Placebo-controlled Study of Pelacarsen (TQJ230) on Cardiovascular Outcomes in Patients With Established Cardiovascular Disease and Elevated Lipoprotein(a)
jRCT2080225280Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2020
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in cardiac morbidity, myocardial infarction (MI), ischemic stroke and 2 more comparing Pelacarsen 80 mg monthly with Placebo (2 arms). Started Jul 2020; status: completed.
02
Drugs
pelacarsen
03
Conditions
cardiac morbiditymyocardial infarction (MI)ischemic strokearteriosclerosis obliteranslipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on jRCT2080225280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225280.